Drug Resistance Rate of New Pulmonary Tuberculosis Patients Treated from the Private Sector in 2003~2005.
- Author:
Young Kil PARK
1
;
Yoon Sung PARK
;
Jeong Ym BAI
;
Hee Jin KIM
;
Woo Jin LEW
;
Chul Hun CHANG
;
Hee Kyung LEE
Author Information
- Publication Type:Original Article
- Keywords: New pulmonary tuberculosis patients; Drug resistance rate; Private sector
- MeSH: Drug Resistance; Humans; Isoniazid; Prevalence; Private Sector; Public Sector; Social Identification; Tuberculosis; Tuberculosis, Pulmonary
- From:Tuberculosis and Respiratory Diseases 2008;64(2):87-94
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Surveillance of TB drug resistance (DR) is essential for providing information on the magnitude and trends in resistance, for developing treatment guidelines and for monitoring the effect of interventions. Up to now national surveys of drug resistance of M. tuberculosis have been conducted four times since 1994 among patients registered at health centers. The purpose of this study is to estimate the prevalence of primary drug resistance among new cases identified in private sector, and to compare it with the previous national drug resistance surveys. METHODS: The study collected results of drug susceptibility testing (DST) performed at the Korean Institute of Tuberculosis by the request of private sector from January 2003 to December 2005, and then finally selected new cases for the analysis from the database of Korean TB Surveillance (KTBS) by matching patients' name and social identification numbers. RESULTS: Of the 5,132 new patients included in the study, 689 (13.4%) patients were found to have drug resistance at least one drug, 530 patients (10.3%) were isoniazid resistant, 195 patients (3.8%) were multi-drug resistant (MDR), and 21 patients (0.4%) were extensively drug resistant (XDR). The rate of drug resistance tended to decrease annually but it was not statistically significant. When compared with previous national DR surveys in 2003 and in 2004 respectively, they were not significantly different. CONCLUSION: The prevalence of DR among new cases managed in the private sector did not show significant difference from that of new patients registered in the public sector in the same year.
